INCB053914 + ruxolitinib

INCB053914 + ruxolitinib is a **combination therapy** under clinical investigation for the treatment of advanced malignancies and myeloproliferative neoplasms (MPNs). INCB053914 is a pan-PIM kinase inhibitor, targeting all three PIM kinases (PIM1, PIM2, PIM3), which are serine/threonine kinases involved in regulating apoptosis and cellular proliferation. Ruxolitinib is a selective inhibitor of Janus kinase 1 and 2 (JAK1, JAK2), which regulates cytokine-mediated signaling pathways in hematologic and inflammatory diseases. Combination of these agents has shown **synergistic effects on suppression of neoplastic cell growth, induction of apoptosis**, and inhibition of persistent myeloproliferation in JAK2-driven preclinical models and patient sample assays. This combination is being developed and clinically tested for improved outcomes in patients with **MPNs, polycythemia vera, essential thrombocythemia, and primary myelofibrosis**[1][2][3][4][5][6].

Other names

INCB053914 + Jakafi